Search
Stannous chloride
go.drugbank.com/drugs/DB11056ApprovedThese complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label].
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. … Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections.
Dihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitDihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis
Mixtures: Duohist DH, EndaCof DHInternational brands: DF-118 ForteSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalIt was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body.
Tildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalThe Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in … [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment
Yellow fever vaccine
go.drugbank.com/drugs/DB10805ApprovedInvestigationalIt is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118 … 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days [FDA
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational(HoFH) under the brand name "Evkeeza". … [A229278] In February 2021, evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalLevodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. … The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
Bilastine
go.drugbank.com/drugs/DB11591ApprovedBilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Products: Nra-bilastine